The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Iron addiction: a novel therapeutic target in ovarian cancer
Open accessAbstract
Ovarian cancer is a lethal malignancy that has not seen a major therapeutic advance in over 30 years. We demonstrate that ovarian cancer exhibits a targetable alteration in iron metabolism. Ferroportin (FPN), the iron efflux pump, is decreased, and transferrin receptor (TFR1), the iron importer, is increased in tumor tissue from patients with high grade but not low grade serous ovarian cancer. A similar profile of decreased FPN and increased TFR1 is observed in a genetic model of ovarian cancer tumor-initiating cells (TICs). The net result of these changes is an accumulation of excess intracellular iron and an augmented dependence on iron for proliferation. A forced reduction in intracellular iron reduces the proliferation of ovarian cancer TICs in vitro, and inhibits both tumor growth and intraperitoneal dissemination of tumor cells in vivo. Mechanistic studies demonstrate that iron increases metastatic spread by facilitating invasion through expression of matrix metalloproteases and synthesis of interleukin 6 (IL-6). We show that the iron dependence of ovarian cancer TICs renders them exquisitely sensitive in vivo to agents that induce iron-dependent cell death (ferroptosis) as well as iron chelators, and thus creates a metabolic vulnerability that can be exploited therapeutically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691
Regulation of Ferroptotic Cancer Cell Death by GPX4
Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., Cheah, J. H., Clemons, P. A., Shamji, A. F., Clish, C. B., et al. (2014) · Cell · doi:10.1016/j.cell.2013.12.010 · Cited by 7,713
Ferroptosis: Death by Lipid Peroxidation
Yang, W. S., & Stockwell, B. R. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.10.014 · Cited by 3,088
The role of iron and reactive oxygen species in cell death
Dixon, S. J., & Stockwell, B. R. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1416 · Cited by 2,381
Ovarian Cancer Development and Metastasis
Lengyel, E. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,672
Iron and cancer: more ore to be mined
Torti, S. V., & Torti, F. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3495 · Cited by 1,621
Self-citationNovel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Dolma, S., Lessnick, S. L., Hahn, W. C., & Stockwell, B. R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00050-3 · Cited by 1,446
Evaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,418
The biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B., & Mills, G. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2644 · Cited by 1,358
Regulation of ferritin genes and protein
Torti, F. M., & Torti, S. V. (2002) · Blood · doi:10.1182/blood.v99.10.3505 · Cited by 1,173
Self-citationDriver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R., Stewart, C., Fereday, S., Caldas, C., deFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 787
Kurrey, N. K., Jalgaonkar, S. P., Joglekar, A. V., Ghanate, A. D., Chaskar, P. D., Doiphode, R. Y., & Bapat, S. A. (2009) · Stem Cells · doi:10.1002/stem.154 · Cited by 655
Vang, R., Shih, I.-M., & Kurman, R. J. (2009) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181b4fffa · Cited by 562
Silva, I. A., Bai, S., McLean, K., Yang, K., Griffith, K., Thomas, D., Ginestier, C., Johnston, C., Kueck, A., Reynolds, R. K., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3175 · Cited by 514
Iron and cancer: recent insights
Manz, D. H., Blanchette, N. L., Paul, B. T., Torti, F. M., & Torti, S. V. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13008 · Cited by 507 · cited 1×
“We tested whether the profile of iron acquisition and retention seen in ovarian cancer TICs was a result of an enhanced dependence on iron (“iron addiction”)(25).”
BackgroundSelf-citationFerroportin and Iron Regulation in Breast Cancer Progression and Prognosis
Pinnix, Z. K., Miller, L. D., Wang, W., D’Agostino, R., Kute, T., Willingham, M. C., Hatcher, H., Tesfay, L., Sui, G., Di, X., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001127 · Cited by 448
Self-citationEpigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells
Baba, T., Convery, P. A., Matsumura, N., Whitaker, R. S., Kondoh, E., Perry, T., Huang, Z., Bentley, R. C., Mori, S., Fujii, S., et al. (2009) · Oncogene · doi:10.1038/onc.2008.374 · Cited by 419
Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
Coward, J., Kulbe, H., Chakravarty, P., Leader, D., Vassileva, V., Leinster, D. A., Thompson, R., Schioppa, T., Nemeth, J., Vermeulen, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0945 · Cited by 390
Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer
Landen, C. N., Goodman, B., Katre, A. A., Steg, A. D., Nick, A. M., Stone, R. L., Miller, L. D., Mejia, P. V., Jennings, N. B., Gershenson, D. M., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0563 · Cited by 382
Self-citationPreferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells
Schonberg, D. L., Miller, T. E., Wu, Q., Flavahan, W. A., Das, N. K., Hale, J. S., Hubert, C. G., Mack, S. C., Jarrar, A. M., Karl, R. T., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.002 · Cited by 349
Origin and molecular pathogenesis of ovarian high-grade serous carcinoma
Kurman, R. J. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt463 · Cited by 336
Ovarian Cancer Pathogenesis: A Model in Evolution
Karst, A. M., & Drapkin, R. (2010) · Journal of Oncology · doi:10.1155/2010/932371 · Cited by 298
Modeling High-Grade Serous Ovarian Carcinogenesis from the Fallopian Tube
Karst, A. M., Levanon, K., & Drapkin, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017300108 · Cited by 280
In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations
Schimanski, L. M., Drakesmith, H., Merryweather-Clarke, A. T., Viprakasit, V., Edwards, J. P., Sweetland, E., Bastin, J. M., Cowley, D., Chinthammitr, Y., Robson, K. J. H., et al. (2005) · Blood · doi:10.1182/blood-2004-11-4502 · Cited by 212
An iron regulatory gene signature predicts outcome in breast cancer
Miller, L. D., Coffman, L. G., Chou, J. W., Black, M. A., Bergh, J., D'Agostino, R., Torti, S. V., & Torti, F. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1870 · Cited by 202 · cited 1×
“An iron acquisition phenotype has now been reported in a number of cancers: breast(34, 35), glioblastoma(36), prostate(37), and others(11).”
BackgroundHepcidin regulation in prostate and its disruption in prostate cancer
Tesfay, L., Clausen, K. A., Kim, J. W., Hegde, P., Wang, X., Miller, L. D., Deng, Z., Blanchette, N., Arvedson, T., Miranti, C. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2465 · Cited by 186
Self-citationQuantifying chromogen intensity in immunohistochemistry via reciprocal intensity.
Nguyen, D. H. A., & Nguyen, D. H. A. (2013) · Protocol Exchange · doi:10.1038/protex.2013.097 · Cited by 160
Torti, S. V., & Torti, F. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3614 · Cited by 158
Self-citationRoss, S. L., Tran, L., Winters, A., Lee, K.-J., Plewa, C., Foltz, I., King, C., Miranda, L. P., Allen, J., Beckman, H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.017 · Cited by 145
IRP2 Regulates Breast Tumor Growth
Wang, W., Deng, Z., Hatcher, H., Miller, L. D., Di, X., Tesfay, L., Sui, G., D'Agostino, R. B., Torti, F. M., & Torti, S. V. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1224 · Cited by 141
Self-citationFunctional consequences of ferroportin 1 mutations
Liu, X.-B., Yang, F., & Haile, D. J. (2005) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2005.04.005 · Cited by 136
Efficient molecular subtype classification of high‐grade serous ovarian cancer
Leong, H. S., Galletta, L., Etemadmoghadam, D., George, J., Study, T. A. O. C., Köbel, M., Ramus, S. J., & Bowtell, D. D. L. (2015) · The Journal of Pathology · doi:10.1002/path.4536 · Cited by 95
Ovary and fimbrial stem cells: biology, niche and cancer origins
Ng, A., & Barker, N. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4056 · Cited by 94
Ovarian cancer stem cells: Are they real and why are they important?
Shah, M. M., & Landen, C. N. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.12.001 · Cited by 94
PIASy-Mediated Sumoylation of Yin Yang 1 Depends on Their Interaction but Not the RING Finger
Deng, Z., Wan, M., & Sui, G. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01761-06 · Cited by 88
Self-citationIroning out cell death mechanisms
Reed, J. C., & Pellecchia, M. (2012) · Cell · doi:10.1016/j.cell.2012.05.009 · Cited by 87
In vitro and in vivo correlates of physiological and neoplastic human Fallopian tube stem cells
Yamamoto, Y., Ning, G., Howitt, B. E., Mehra, K. K., Wu, L., Wang, X., Yue, H., Kern, F., Wei, T. S., Zhang, T., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4649 · Cited by 75
Self-citationZou, M., Zhang, X., & Xu, C. (2015) · Cellular Oncology · doi:10.1007/s13402-015-0251-7 · Cited by 65
Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer
Dijkgraaf, E. M., Welters, M. J. P., Nortier, J. W. R., van der Burg, S. H., & Kroep, J. R. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802002797 · Cited by 64
Revisiting the pathogenesis of ovarian cancer: the central role of the fallopian tube
Dietl, J. (2013) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-013-3041-3 · Cited by 53
Lui, G. Y. L., Kovačević, Ž., Menezes, S. V., Kalinowski, D. S., Merlot, A. M., Sahni, S., & Richardson, D. R. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.096529 · Cited by 50
Dai, J., Huang, C., Wu, J., Yang, C., Frenkel, K., & Huang, X. (2004) · Toxicology · doi:10.1016/j.tox.2004.06.009 · Cited by 41
Li, H.-X., Lu, Z., Shen, K., Cheng, W.-J., Malpica, A. L., Zhang, J., Wei, J., Zhang, Z. H., & Liu, J. (2014) · Europe PMC (PubMed Central) · Cited by 37
The Life and Times of Low-Grade Serous Carcinoma of the Ovary
Gershenson, D. M. (2013) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2013.33.e195 · Cited by 35
Cited by
Ferroptosis: past, present and future
Li, J., Cao, F., Yin, H.-L., Huang, Z.-J., Lin, Z.-T., Mao, N., Sun, B., & Wang, G. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2298-2 · Cited by 4,171
Targeting Ferroptosis to Iron Out Cancer
Hassannia, B., Vandenabeele, P., & Vanden Berghe, T. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.04.002 · Cited by 2,478
Ferroptosis, a new form of cell death: opportunities and challenges in cancer
Mou, Y., Wang, J., Wu, J., He, D., Zhang, C., Duan, C., & Li, B. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0720-y · Cited by 1,930
Role of GPX4 in ferroptosis and its pharmacological implication
Seibt, T. M., Proneth, B., & Conrad, M. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.09.014 · Cited by 1,520
The chemical basis of ferroptosis
Conrad, M., & Pratt, D. A. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0408-1 · Cited by 1,002
Metadata
- Authors
- Basuli, D., Tesfay, L., Deng, Z., Paul, B., Yamamoto, Y., Ning, G., Xian, W., McKeon, F., Lynch, M., Crum, C. P., Hegde, P., Brewer, M., Wang, X., Miller, L. D., Dyment, N., Torti, F. M., & Torti, S. V.
- Venue
- Oncogene
- Published
- 2017-03-20
- Volume
- 36
- Issue
- 29
- Pages
- 4089-4099
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2604049161
- Cited by
- 465
- References
- 45
- FWCI
- 18.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.